|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM327645075 |
| 003 |
DE-627 |
| 005 |
20231225201238.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108792
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1092.xml
|
| 035 |
|
|
|a (DE-627)NLM327645075
|
| 035 |
|
|
|a (NLM)34217849
|
| 035 |
|
|
|a (PII)S1521-6616(21)00129-7
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Millán, Olga
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 16.09.2021
|
| 500 |
|
|
|a Date Revised 16.09.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a This study evaluate the potential of plasmatic CXCL-10 (pCXCL-10) as a pre&post transplantation prognostic and diagnostic biomarker of T-cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR) and subclinical rejection (SCR) risk in adult kidney recipients considering BKV and CMV infections as possible clinical confounder factors. Twenty-eight of 100 patients included experienced rejection (TCMR:14; ABMR:14); 8 SCR; 13 and 16 were diagnosed with BKV and CMV infection, respectively. Pre-transplantation pCXCL-10 was significantly increased in TCMR and ABMR and post-transplantation in TCMR, ABMR and SCR compared with nonrejectors. All CMV+ patients showed pCXCL-10 levels above the cutoff values established for rejection whereas the 80% of BKV+ patients showed pCXCL-10 concentration < 100 pg/mL. pCXCL-10 could improve pre-transplantation patient stratification and immunosuppressive treatment selection according to rejection risk; and after kidney transplantation could be a potential early prognostic biomarker for rejection. Clinical confounding factor in BKV+ and particularly in CMV+ patients must be discarded
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Multicenter Study
|
| 650 |
|
4 |
|a Observational Study
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a ABMR
|
| 650 |
|
4 |
|a BKV
|
| 650 |
|
4 |
|a Biological matrix
|
| 650 |
|
4 |
|a CMV
|
| 650 |
|
4 |
|a CXCL-10
|
| 650 |
|
4 |
|a Kidney transplantation
|
| 650 |
|
4 |
|a Rejection (TCMR
|
| 650 |
|
4 |
|a SCR)
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a CXCL10 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Chemokine CXCL10
|2 NLM
|
| 650 |
|
7 |
|a Isoantibodies
|2 NLM
|
| 700 |
1 |
|
|a Rovira, Jordi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Guirado, Lluis
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Espinosa, Cristina
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Budde, Klemens
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sommerer, Claudia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Piñeiro, Gaston J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Diekmann, Fritz
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Brunet, Mercè
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 229(2021) vom: 15. Aug., Seite 108792
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:229
|g year:2021
|g day:15
|g month:08
|g pages:108792
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108792
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 229
|j 2021
|b 15
|c 08
|h 108792
|